First candidate antibiotic is effective against all tested MRSA strains
· May offer treatment against multiple drug-resistant infections
· Proprietary to Galapagos, based on novel target DNA pol III alpha (DnaE)
· Clinical development of first antibiotic initiated
Mechelen, Belgium; 26 November 2012 - Galapagos NV (Euronext: GLPG) announced today that it has discovered an entirely new class of antibiotics. The Company has selected a candidate drug that shows strong activity against all tested drug resistant Staphylococcus aureus, including hospital and community acquired MRSA strains.
Bacterial infections that have become resistant to all existing antibiotics pose a pressing healthcare problem because treatment options for patients become very limited. MRSA is the best known example: a potentially life-threatening infection that occurs most frequently among patients in hospitals. The novel Galapagos candidate antibiotic shows strong activity against all tested drug resistant bacteria.
This newly discovered antibiotic works by inhibiting the target DNA pol III alpha, an enzyme present in all bacteria and essential for their growth; this target is absent in humans. The novel mode of action - inhibition of DNA pol III alpha - may be used to explore a variety of novel antibiotics, targeting bacteria for which resistance to current antibiotics has emerged.
Using this novel target, Galapagos has selected a first candidate antibiotic, CAM-1, to enter drug development. CAM-1 was tested against more than 250 different bacterial strains and effectively killed 100% of all drug resistant Staph. aureus, including MRSA. CAM-1 shows better efficacy than standard antibiotics, as shown by in vivo bacterial infection models. Galapagos aims to enter the clinic in the first quarter 2014, with a Proof of Concept study thereafter. This novel antibiotic program, including all compounds targeting MRSA, is fully proprietary to Galapagos.
"Selection of a candidate antibiotic in our MRSA development program is an important step toward realizing the full potential of our unique anti-bacterial program," said Dr Piet Wigerinck, Chief Scientific Officer of Galapagos. "Our antibiotics have a novel mode of action which brings all tested MRSA strains to a complete halt. Combined with a diagnostic test, these compounds could bring a real solution to MRSA infections."
Drug resistant infections including MRSA (Methicillin Resistant Staphylococcus aureus) occur most frequently among patients in healthcare settings. Globally, MRSA treatment with antibiotics generates an estimated $4 billion in annual revenues. Development of new treatments within existing classes of antibiotics is complicated by the short timeframe in which resistance to the antibiotic emerges. Regulators encourage development of narrow spectrum antibiotics in order to address this dilemma. Current advancements in rapid diagnostic tests to identify the bacterial strain responsible for the infection provide an opportunity for the development of targeted, narrow spectrum antibiotics.
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size clinical stage biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The company is progressing its JAK1 inhibitor GLPG0634, as well as one of the largest pipelines in biotech, with four programs in development and over 30 discovery programs. The Galapagos Group has over 800 employees and operates facilities in six countries, with global headquarters in Mechelen, Belgium. More info at: www.glpg.com
Dr Piet Wigerink, Chief Scientific Officer
Tel. +32 477 627103
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
"MRSA Drug Futures,"Epsicom, Sept. 2010